Imagen de Portada

Metformin monotherapy versus predominantly older non‐metformin antidiabetic medications for cerebrovascular risk in early type 2 diabetes management

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Mingyang Sun, Zhongyuan Lu, Wan‐Ming Chen, Shuang Lv, Ningning Fu, Yitian Yang, Yangyang Wang, Mengrong Miao, Szu‐Yuan Wu, Jiaqiang Zhang
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Diabetes, Obesity and Metabolism
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Long‐term delirium and survival outcomes in patients treated with GLP ‐1 receptor agonists versus metformin in type 2 diabetes: A population‐based cohort study
por: Mingyang Sun, et al.
Publicado: (2025)

Sodium‐glucose cotransporter‐2 inhibitors and subtype‐specific dementia risk: A multinational and multiethnic cohort study
por: Mingyang Sun, et al.
Publicado: (2025)

Baseline HbA1c and dementia risk at SGLT2i initiation in type 2 diabetes
por: Jiaqiang Zhang, et al.
Publicado: (2025)

Metformin lowers risk of hearing loss and mortality in type 2 diabetes
por: Chun‐Chih Huang, et al.
Publicado: (2024)

Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin
por: Jianglan Long, et al.
Publicado: (2024)

Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy ( EFFORT ): A 24‐week, randomized, open‐label, multicenter trial
por: So Ra Kim, et al.
Publicado: (2026)

Associations of metformin and sulfonylurea on vascular complications in early‐ and late‐onset type 2 diabetes: A cohort study
por: Zongming Yang, et al.
Publicado: (2026)

Exploring the value of ChatGPT in selecting antidiabetic agents for type 2 diabetes
por: Seol A. Jang, et al.
Publicado: (2025)

Beyond diabetes: Testing long‐term metformin adherence for dementia prevention
por: Timothy Daly, et al.
Publicado: (2025)

Metformin continuation post‐metabolic bariatric surgery and relapse of diabetes
por: Dror Dicker, et al.
Publicado: (2024)

Metformin beyond type 2 diabetes: Emerging and potential new indications
por: John R. Petrie
Publicado: (2024)

Metformin use associated with lower rate of hospitalization for influenza in individuals with diabetes
por: Elizabeth Greene, et al.
Publicado: (2024)

Anti‐ VEGF monotherapy versus anti‐ VEGF therapy combined with laser or intravitreal glucocorticoid therapy for diabetic macular edema: A Bayesian network meta‐analysis
por: Xiaofei Yang, et al.
Publicado: (2025)

The cost‐utility and budget impact analyses of Tirzepatide versus once‐weekly Semaglutide as add‐on therapy to metformin in patients with type 2 diabetes mellitus in China
por: Sihua Wang, et al.
Publicado: (2025)

SGLT2 inhibitor or metformin as standard treatment in early‐stage type 2 diabetes? Baseline data in SMARTEST , a novel, decentralised, register‐based randomised trial on prevention of diabetic complications
por: Jan W. Eriksson, et al.
Publicado: (2025)

Efficacy and safety of chiglitazar add‐on to metformin in type 2 diabetes mellitus ( RECAM study)
por: Leili Gao, et al.
Publicado: (2025)

A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study
por: Tae Seo Sohn, et al.
Publicado: (2024)

The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
por: Ming Liu, et al.
Publicado: (2024)

Clinical effectiveness and cost‐effectiveness of first‐line early combination of dipeptidyl peptidase 4 inhibitors and metformin in patients with type 2 diabetes in Taiwan: A modelling study
por: Thi Thuy Dung Nguyen, et al.
Publicado: (2025)

Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta‐analysis
por: Leonardo A. Mesquita, et al.
Publicado: (2024)

Retagliptin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
por: Lixin Guo, et al.
Publicado: (2024)

A comparative study of the effects of imeglimin add‐on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low‐dose metformin ( MEGMI‐CGM study)
por: Akihiro Takahashi, et al.
Publicado: (2024)

Single versus repeat diabetes testing in older adults: Observations from the STAREE clinical trial
por: Jia Yong Tan, et al.
Publicado: (2026)

Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial
por: Yao Wang, et al.
Publicado: (2024)

Impact of the timing of metformin administration on the plasma lactate response to intraduodenal glucose infusion in type 2 diabetes
por: Cong Xie, et al.
Publicado: (2024)

The efficacy and safety of ISIS 449884 injection as monotherapy in patients with type 2 diabetes: A randomized phase II study
por: Linong Ji, et al.
Publicado: (2024)

Metformin slows intestinal glucose absorption in type 2 diabetes, irrespective of the timing of its administration
por: Malcolm J. Borg, et al.
Publicado: (2025)

Comparative efficacy and safety of Glucagon‐like pepetide‐1 receptor agonists with metformin in Asian versus non‐Asian patients with type 2 diabetes: A systematic review and meta‐analysis
por: Wenxuan Li, et al.
Publicado: (2025)

Cofrogliptin once every 2 weeks as add‐on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double‐blind, non‐inferiority trial
por: Qian Ren, et al.
Publicado: (2024)

Patterns of metformin use and glycated haemoglobin trends among patients with newly diagnosed type 2 diabetes in Alberta, Canada
por: Tina Kim, et al.
Publicado: (2024)

Association of Metformin use with risk of dementia in patients with type 2 diabetes: A systematic review and meta‐analysis
por: Chunbian Tang, et al.
Publicado: (2025)

Triple oral therapy with metformin, DPP ‐4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025)
por: Miao Yu, et al.
Publicado: (2025)

Partial non‐adherence to antidiabetic therapy undermines diabetes management and correlates with treatment complexity: A cross‐sectional study using blood plasma analysis
por: Vojtěch Škop, et al.
Publicado: (2025)

The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec + insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
por: Yiming Mu
Publicado: (2024)

Similarities and differences in the intestinal actions of metformin and imeglimin
por: Kenji Sugawara, et al.
Publicado: (2025)

Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study
por: Kyung Ah Han, et al.
Publicado: (2024)

Time trends and regional variation in utilization of antidiabetic medicines in China, 2015–2022
por: Jieqiong Zhang, et al.
Publicado: (2024)

One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA
por: Mengqing Zhang, et al.
Publicado: (2024)

Correction to “Defining diabetes status using medication groups in Medicare data: Trends in prescribing diabetes medications to patients without a diabetes diagnosis over time”
Publicado: (2024)

Representation of women in randomized controlled trials of novel antidiabetic drugs: A cohort study
por: Genya Aharon‐Hananel, et al.
Publicado: (2024)